Headlines

Merck & Co. (MRK) says Phase 3 TroFuse-015 trial of sac-TMT improved overall survival in advanced gastroesophageal adenocarcinoma but did not meet its progression-free survival endpoint

Newsquawk Staff ·

Merck & Co. (MRK) says Phase 3 TroFuse-015 trial of sac-TMT improved overall survival in advanced gastroesophageal adenocarcinoma but did not meet its progression-free survival endpoint.

What it means

A split readout of this kind, overall survival met with the progression-free endpoint missed, sits in a well-worn category in oncology. Regulators in this space have historically treated overall survival as the gold-standard endpoint, and approvals on the strength of OS alone, without a PFS benefit, are not without precedent; the cleaner the survival result, the weaker the PFS miss tends to matter for the filing path. The countervailing pattern is that mixed readouts have often been sold first and analysed later, particularly where the drug is one asset in a broad late-stage programme and the market's focus is on the higher-value indications rather than the indication in question. The competitive angle is the sharper one: this is a TROP2-targeted antibody-drug conjugate, a crowded class where relative efficacy across tumour types, and the margin of the OS benefit rather than its mere statistical significance, is what separates winners. What is worth watching next is the full data presentation, including hazard ratios and subgroup detail, whether management signals a filing intention on this dataset, and any read-across commentary for the other indications in the programme. A single readout of this kind rarely re-rates the name on its own; the follow-ons determine that.

Related headlines